rare disease
NHS signs deal with Orchard for pricey Libmeldy gene therapy
Phil Taylor
gene therapy, HEOR, Libmeldy, NHS, NICE, Orchard Therapeutics, paediatric, rare disease
0 Comment
Pharming preps filing for rare disease drug leniolisib after trial win
Phil Taylor
activated PI3K delta syndrome, leniolisib, Novartis, Pharming, rare disease
0 Comment
After FDA setback, Ipsen gets first OK for rare disease drug palovarotene
Phil Taylor
Canada, garetosmab, Ipsen, Orphan drug, rare disease, Regeneron, Sohonos
0 Comment
Sarepta says early filing for DMD gene therapy may be back on
Phil Taylor
Duchenne muscular dystrophy, gene therapy, Pfizer, rare disease, Sarepta, Solid Biosciences
0 Comment
News/ News/ Sales and Marketing
Regeneron hands ex-US rights to HoFH drug Evkeeza to Ultragenyx
Phil Taylor
Evkeeza, homozygous familial hypercholesterolaemia, rare disease, Regeneron, Sales and Marketing, Ultragenyx
0 Comment
Biogen looks beyond Spinraza in SMA with Ionis deal
Phil Taylor
Biogen, Evrysdi, Ionis Pharmaceuticals, Novartis, rare disease, Roche, spinal muscular atrophy, Spinraza, Zolgensma
0 Comment
Applied Therapeutics slumps as FDA seeks more data on lead drug
Phil Taylor
Applied Therapeutics, galactosaemia, inherited disease, rare disease, regulatory
0 Comment
Boehringer’s spesolimab data raises hope for serious skin disease
Phil Taylor
Boehringer Ingelheim, dermatology, Immunology and inflammation, rare disease, spesolimab
0 Comment